Based on years of grant-funded R&D and protected by 6 issued and 2 pending patents, the AQ Shunt competes in the growing $5B surgical glaucoma treatment market.
Based on years of grant-funded R&D and 6 issued and 2 pending patents, the AQ Shunt is used to prevent blindness within the rapidly growing $5B glaucoma market. The ASP will be $775 in and is reimbursed in the US. COG is less than $20. AQ BioMed plans to enter the surgical glaucoma implant market and achieve over $15M in sales in the next 3 to 5 years. AQ has been awarded a $250K grant by the state of Co. and is raising matching funds.